Malarone® induced pancreatitis and alopecia in a dog: a case report

被引:0
作者
Choi, Hyeong-Il [1 ]
Ko, Hui-Yeon [1 ]
Shin, In-Sik [2 ]
Kim, Ha-Jung [1 ]
机构
[1] Chonnam Natl Univ, Coll Vet Med, Dept Internal Med, Gwangju 61168, South Korea
[2] Chonnam Natl Univ, Coll Vet Med, BK21 Project Team, Gwangju 61168, South Korea
基金
新加坡国家研究基金会;
关键词
Adverse drug reaction; Alopecia; Malarone (R); Pancreatitis; ATOVAQUONE; TRIMETHOPRIM;
D O I
10.1186/s12917-019-2056-9
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background Malarone (R) is a drug used for the treatment of malaria in humans. This drug is also particularly effective in the treatment of canine Babesia gibsoni infections. Malarone (R) is rarely used in dogs, and its adverse effects have not been widely reported. Its mechanism of action is related to the inhibition of cytochrome b and electron transport in the cell. This is the first known report of the development of acute pancreatitis and alopecia in a dog following the administration of Malarone (R). Case presentation A 3-year-old, intact, female Maltese was referred to our clinic with intermittent vomiting and sudden, generalized alopecia. Two months previously, the dog had been prescribed Malarone (R) for the treatment of a suspected B. gibsoni infection. The dog was evaluated using hematology, radiography, ultrasonography, a PCR for Babesia detection, and a canine pancreatic lipase immunoreactivity (cPLI) assay. The result of the PCR test was negative, whereas the cPLI assay yielded a positive result. Dermatologic examination revealed bacterial infection with hair cycle arrest. Conclusions Based on these findings, drug-induced acute pancreatitis and alopecia with superficial pyoderma were diagnosed. Malarone (R) may induce severe adverse reactions in dogs. Therefore, careful monitoring for adverse effects is required when using Malarone (R) in dogs.
引用
收藏
页数:3
相关论文
共 9 条
[1]   Antiparasitic agent atovaquone [J].
Baggish, AL ;
Hill, DR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1163-1173
[2]  
Birkenheuer AJ, 2004, J VET INTERN MED, V18, P494, DOI 10.1892/0891-6640(2004)18<494:EOCAAA>2.0.CO
[3]  
2
[4]   Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides [J].
Chan, C ;
Montaner, J ;
Lefebvre, EA ;
Morey, G ;
Dohn, M ;
McIvor, RA ;
Scott, J ;
Marina, R ;
Caldwell, P .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :369-376
[5]  
DAVIDSON NM, 1986, LANCET, V1, P384
[6]   ADVERSE EVENTS ASSOCIATED WITH TRIMETHOPRIM-SULFAMETHOXAZOLE AND ATOVAQUONE DURING THE TREATMENT OF AIDS-RELATED PNEUMOCYSTIS-CARINII PNEUMONIA [J].
HUGHES, WT ;
LAFON, SW ;
SCOTT, JD ;
MASUR, H .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1295-1301
[7]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[8]   Fortnightly review - Adverse drug reactions [J].
Pirmohamed, M ;
Breckenridge, AM ;
Kitteringham, NR ;
Park, BK .
BRITISH MEDICAL JOURNAL, 1998, 316 (7140) :1295-1298
[9]  
Pudney M., 1999, J TRAVEL MED, V6, pS12